Following a strong run over the last year, brokers see further upside for shares of FleetPartners following first half results
Life360 has doubled in share price since its March earnings result, but brokers believe further re-rating is still on the cards
As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission
SiteMinder’s March quarter update showed the company is on track to reach positive earnings and cash flow next quarter and new product launches offer growth
The New Criterion’s Tim Boreham uncovers the potential of 4D Medical in the USA
Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports
The New Criterion’s Tim Boreham explains the benefits of royalties and where to access them via the ASX
Tim Boreham highlights Hydrix as one of the most innovative small-cap healthcare companies on the ASX
Brokers welcome Life360’s new advertising initiative unveiled at the same time as FY23 results and FY24 guidance which both exceeded expectations
Capitol Health’s first half results exceeded brokers’ expectations with higher margins thanks largely to stringent cost control